GH Research PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GHRS research report →
Range $39 – $65
Price Chart
About the company
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients.
- CEO
- Velichka Valcheva
- IPO
- 2021
- Employees
- 73
- HQ
- Dublin, DU, IE
Get TickerSpark's AI analysis on GHRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.97B
- P/E
- -28.68
- PEG
- 1.00
- P/S
- 0.00
- P/B
- 5.31
- EV/EBITDA
- -26.28
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -20.86%
- ROIC
- -19.85%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-335,000+0.0%
- Op Income
- $-60,675,999
- Net Income
- $-48,257,999-23.9%
- EPS
- $-0.79-5.3%
- OCF Growth
- -3.0%
- FCF Growth
- -3.2%
- 52W High
- $31.44
- 52W Low
- $11.83
- 50D MA
- $26.66
- 200D MA
- $18.97
- Beta
- 1.29
- RSI (14)
- 51
- Avg Volume
- 304.08K
No earnings-call transcripts are available for GHRS yet.
- Free Float
- 74.2%
- Shares Outstanding
- 68.56M
- Float Shares
- 50.88M
of shares held by institutions
58 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cubist Systematic Strategies, LLC | 22.73K | ▲ 22.73K |
Held by 22 ETFs
Biggest fund positions in GHRS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 26 | Moore Duncan | other | 2,202 |
| Aug 11, 26 | Hanley Dermot John | other | 2,202 |
| Aug 11, 26 | Forer Michael | other | 100,000 |
| Aug 11, 26 | Forer Michael | other | 2,202 |
| Mar 18, 26 | Moore Duncan | other | 0 |
| Mar 18, 26 | Moore Duncan | other | 4,667 |
| Mar 18, 26 | Cameron Aaron Luke | other | 33,211 |
| Mar 18, 26 | Cameron Aaron Luke | other | 100,000 |
| Mar 18, 26 | Cameron Aaron Luke | other | 25,000 |
| Mar 18, 26 | Hanley Dermot John | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GHRS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on GHRS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 6
Why Is GH Research Stock Trading Higher on Thursday?
benzinga.com · Jul 16
CleanSpark shares surge after company secures $6.6B data center lease agreement
proactiveinvestors.com · Jul 14
Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity
proactiveinvestors.com · Jul 14
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
proactiveinvestors.com · Jul 13
GH Research Announces Publication of Phase 2a Postpartum Depression Results
globenewswire.com · Jun 4
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
seekingalpha.com · May 20
These Analysts Revise Their Forecasts On GH Research After Q1 Results
benzinga.com · May 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.